We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

47 hedge funds and large institutions have $17.9M invested in Clearside Biomedical in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.16% less ownership

Funds ownership: 1.39% → 1.23% (-0.16%)

8% less funds holding

Funds holding: 51 → 47 (-4)

20% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 15

25% less capital invested

Capital invested by funds: $23.8M → $17.9M (-$5.86M)

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Holders
47
Holders Change
-4
Holders Change %
-7.84%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
15
Closed
9
Calls
$80K
Puts
–
Net Calls
+$80K
Net Calls Change
-$24K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$450K
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$365K
3
BlackRock
BlackRock
New York
+$51.4K
4
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$47.7K
5
Renaissance Technologies
Renaissance Technologies
New York
+$46.2K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$2.34M
2
JJ
Johnson & Johnson
New Jersey
-$260K
3
CP
Castleview Partners
Texas
-$248K
4
Millennium Management
Millennium Management
New York
-$211K
5
Jane Street
Jane Street
New York
-$191K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.69M +$450K +23,279 +14%
RA
2
Rosalind Advisors
Ontario, Canada
$3.37M – – –
AC
3
Armistice Capital
New York
$2.78M -$2.34M -121,333 -46%
CG
4
Carmignac Gestion
France
$2.77M – – –
BlackRock
5
BlackRock
New York
$1.04M +$51.4K +2,661 +5%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$874K +$38.8K +2,006 +5%
Renaissance Technologies
7
Renaissance Technologies
New York
$757K +$46.2K +2,393 +7%
Assenagon Asset Management
8
Assenagon Asset Management
Luxembourg
$368K +$365K +18,880 New
State Street
9
State Street
Massachusetts
$267K +$15.2K +787 +6%
First Manhattan
10
First Manhattan
New York
$228K – – –
Morgan Stanley
11
Morgan Stanley
New York
$190K -$9.08K -470 -5%
Northern Trust
12
Northern Trust
Illinois
$173K -$97 -5 -0.1%
BCM
13
Bridgeway Capital Management
Texas
$169K -$251 -13 -0.1%
BWM
14
Brown Wealth Management
Illinois
$130K -$12.9K -666 -9%
Citadel Advisors
15
Citadel Advisors
Florida
$126K +$34.1K +1,764 +38%
NFC
16
Northeast Financial Consultants
Connecticut
$121K – – –
CAPTRUST Financial Advisors
17
CAPTRUST Financial Advisors
North Carolina
$113K +$47.7K +2,467 +74%
Marshall Wace
18
Marshall Wace
United Kingdom
$80.8K -$8.17K -423 -9%
XT
19
XTX Topco
Cayman Islands
$70.6K +$44.3K +2,291 +172%
SF
20
Synovus Financial
Georgia
$69K – – –
Millennium Management
21
Millennium Management
New York
$55.8K -$211K -10,936 -79%
BCV
22
Banque Cantonale Vaudoise
Switzerland
$52K – – –
Prudential Financial
23
Prudential Financial
New Jersey
$46K +$19.6K +1,013 +75%
Stifel Financial
24
Stifel Financial
Missouri
$39.7K -$11K -567 -22%
Jane Street
25
Jane Street
New York
$37.3K -$191K -9,867 -84%
1
2 3

CLSD Hedge Fund Activity: Q2 2024 in Review

47 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2024, worth a combined $17.9M — down 25% from $23.8M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CLSD and 6 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 12 added.

The largest buyer was Vanguard Group, adding an estimated $450K. The largest seller was Armistice Capital, cutting an estimated $2.34M.

  • 47 institutional investors held Clearside Biomedical (CLSD) as of Q2 2024, down from 51 in Q1 2024.
  • Funds reported $17.9M of Clearside Biomedical stock for Q2 2024, down 25% quarter-over-quarter.
  • 6 funds opened new Clearside Biomedical positions in Q2 2024 and 9 closed out, a net change of -3 holders.
  • The largest Clearside Biomedical buyer in Q2 2024 was Vanguard Group, an estimated $450K added.
  • The largest Clearside Biomedical seller in Q2 2024 was Armistice Capital, an estimated $2.34M sold.

Based on aggregated 13F filings for Q2 2024.